WATCH | The Dan Corder Report

JOHANNESBURG - A company called Gilead Science has made a deal to distribute Lenacapavir at very affordable rates in 120 countries, including South Africa.

Lenacapavir is already an approved HIV treatment but, until now, it was for sale in the US for $42,250 a year, which is close to R800,000. 

Now, affordable generics are going to be created, and researchers speculate that Lenacapavir could be produced and sold for just $40 per patient per year, and that would still make profit for the producers.